A Randomized, Double-Blind, Placebo-Controlled Study of Benfluorex in HIV-Infected Patients with Insulin Resistance or Impaired Glucose Tolerance

2009 ◽  
Vol 10 (1) ◽  
pp. 33-40 ◽  
Author(s):  
I. Poizot-Martin ◽  
M.P. Drogoul-Vey ◽  
D. Di Stefano ◽  
E. Jouve ◽  
G. Fabre ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effect of Coenzyme Q10 on Insulin Resistance in Korean Patients with Prediabetes: A Pilot Single-Center, Randomized, Double-Blind, Placebo-Controlled Study

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Ja-Young Yoo ◽  
Keun-Sang Yum
Keyword(s):  
Insulin Resistance ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Coenzyme Q10 ◽  
Controlled Trial ◽  
Controlled Study ◽  
Model Assessment ◽  
Single Center ◽  
Double Blind ◽  
Double Blind Placebo

Introduction. This study aimed to examine whether administration of coenzyme Q10, an antioxidant, improves insulin resistance in patients with prediabetes. The study design was a pilot single-center, randomized, double-blind, placebo-controlled trial. Methods. This pilot single-center, randomized, double-blind, placebo-controlled trial included a total of 80 adults (aged ≥20 years) with impaired glucose tolerance. After the initial screening visit, subjects were assigned to either the experimental (n = 40) or placebo (n = 40) group via simple randomization. Insulin resistance was represented as the insulin resistance index estimated by homeostasis model assessment (HOMA-IR). Results. After the 8-week treatment period, the coenzyme group exhibited a significant decrease in the HOMA-IR (P < .001). The free oxygen radical and coenzyme Q10 concentrations were found to correlate significantly (P < .001). However, no significant changes in fasting blood glucose, insulin, and glycated hemoglobin levels were observed in either group. Additionally, no adverse events occurred in either group. Conclusion. Patients with prediabetes who were administered coenzyme Q10 showed a significant reduction in HOMA-IR values. Therefore, administration of coenzyme Q10 in patients with impaired glucose tolerance may slow the progression from prediabetes to overt diabetes.

Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study"

2017 ◽  
Vol 31 (7) ◽  
pp. 1248
Author(s):  
Giuseppe Derosa ◽  
Pamela Maffioli ◽  
Angela D'Angelo ◽  
Elena Fogari ◽  
Lucio Bianchi ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Retraction Notice ◽  
Oral Fat Load

scholarly journals Effects of Metformin on the Regulation of Free Fatty Acids in Insulin Resistance: A Double-Blind, Placebo-Controlled Study

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Manuel Castro Cabezas ◽  
Jeroen P. H. van Wijk ◽  
Jan Willem F. Elte ◽  
Boudewijn Klop
Keyword(s):  
Insulin Resistance ◽  
Fatty Acids ◽  
Free Fatty Acids ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

2002 ◽  
Vol 87 (12) ◽  
pp. 5503-5506 ◽  
Author(s):  
S. Füllert ◽  
F. Schneider ◽  
E. Haak ◽  
H. Rau ◽  
K. Badenhoop ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Cardiovascular Disease ◽  
Arterial Hypertension ◽  
Controlled Study ◽  
Diabetic Patients ◽  
Prediabetic State ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Increased Risk ◽  
Pioglitazone Treatment

Abstract Hypertension is often associated with insulin resistance, dyslipidemia and obesity, which indicate a prediabetic state and increased risk of cardiovascular disease. Pioglitazone treatment of patients with type 2 diabetes reduces insulin resistance and improves lipid profiles. The present double-blind placebo-controlled study is the first study to report effects of pioglitazone in non-diabetic patients with arterial hypertension. Following a one week run-in, 60 patients were randomized to receive either pioglitazone (45 mg/day) or placebo for 16 weeks. Insulin sensitivity (M-value) increased by 1.2 ± 1.7 mg/min/kg with pioglitazone compared with 0.4 ± 1.4 mg/min/kg (P = 0.022) with placebo. HOMA index was decreased (−22.5 ± 45.8) by pioglitazone but not by placebo (+0.8 ± 26.5; P &lt; 0.001). Decreases in fasting insulin and glucose were significantly (P = 0.002 and P = 0.004, respectively) greater with pioglitazone than placebo. Body weight did not change significantly with either treatment. HDL-cholesterol was increased and apolipoprotein B was decreased to a significantly greater extent with pioglitazone. There was a significantly (P = 0.016) greater decrease from baseline in diastolic blood pressure with pioglitazone. These changes would suggest improved glucose metabolism and a possible reduction in risk of cardiovascular disease with pioglitazone treatment of non-diabetic patients with arterial hypertension.

Sign in / Sign up

Export Citation Format

Share Document